ADUS
Addus HomeCare Corporation
ADUS has a slight edge over OSCR overall, supported by stronger valuation and lower modeled downside.
OSCR
Oscar Health, Inc.
OSCR offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
ADUS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
ADUS's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ADUS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 17x | $124 | — |
| Current | 21x | $124 | — |
| Cheap | 24x | $146 | +18% |
| Fair | 30x | $180 | +46% |
| Expensive | 48x | $286 | +131% |
Historical ranges are pointers, not guarantees.
ADUS's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 17x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over ADUS in the historical PE scenario, which offers more potential upside but is not a forecast.
ADUS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for ADUS, with profitability holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over ADUS on the outlook, with more favorable profitability expectations.
ADUS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $7.47 | +24% |
| Q3 2026 | $6.01 | +29% |
| Q2 2026 | $5.71 | +26% |
| Q1 2026 | $5.42 | +23% |
| Q4 2025 | $5.22 | +23% |
| Q3 2025 | $4.66 | +6.9% |
| Q2 2025 | $4.52 | +7.4% |
| Q1 2025 | $4.42 | +10% |
| Q4 2024 | $4.23 | +10% |
ADUS has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ADUS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $387.7M | +7% |
| Q2 2026 | $377.4M | +8% |
| Q1 2026 | $363.6M | +7.7% |
| Q4 2025 | $373.1M | +26% |
| Q3 2025 | $362.3M | +25% |
| Q2 2025 | $349.4M | +22% |
| Q1 2025 | $337.7M | +20% |
| Q4 2024 | $297.1M | +7.5% |
ADUS's revenue has grown year over year every quarter since late 2020: $388M last quarter, up 7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 10% | +1.2 points |
| Q2 2026 | 10% | +0.9 points |
| Q1 2026 | 9.4% | +0.3 points |
| Q4 2025 | 11% | +2.3 points |
| Q3 2025 | 9.1% | +0.1 points |
| Q2 2025 | 9.4% | +0.3 points |
| Q1 2025 | 9% | +0.6 points |
| Q4 2024 | 9.1% | -1.1 points |
ADUS has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ADUS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ADUS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $38.8M | -21% |
| Q2 2026 | $38.7M | +82% |
| Q1 2026 | $50.7M | +197% |
| Q4 2025 | $16.1M | +85% |
| Q3 2025 | $49.3M | +5.9% |
| Q2 2025 | $21.3M | +20% |
| Q1 2025 | $17.1M | -54% |
| Q4 2024 | $8.7M | -65% |
ADUS generated $144M in free cash flow over the past year, up 50% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ADUS on cash flow, with more consistent year-over-year improvement.
ADUS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +102K shares |
| 1 year | +1% | +184K shares |
| 3 years | +14% | +2.3M shares |
| 5 years | +16% | +2.5M shares |
| Available history | +17% | +2.7M shares |
ADUS has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ADUS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.2x | Net Cash |
| Q1 2026 | -0.1x | Net Cash |
| Q4 2025 | 0.3x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.6x | Very low |
| Q1 2025 | 0.8x | Very low |
| Q4 2024 | 1.0x | Healthy |
ADUS has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over ADUS on leverage, with a lower net debt burden relative to earnings.
ADUS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 63.4 | Neutral |
| Stochastic | 75.9 | Neutral |
ADUS's weekly RSI is 63 (neutral) and its Stochastic is 76 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ADUS PE vs Healthcare Sector
| Metric | ADUS | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 26x | 20% below |
| PE % | 8 | 29 | 21 pts below |
ADUS is trading at 21x earnings, a 20% discount to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over ADUS on valuation relative to its sector.
ADUS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $118.8 | 4.2% above |
| 20 week MA | $116.7 | 6.1% above |
| 50 week MA | $107.7 | 15% above |
| 100 week MA | $110.0 | 13% above |
| 200 week MA | $106.5 | 16% above |
ADUS is in an uptrend: it's above all five of its weekly moving averages, and 16% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
ADUS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $95.6 | $115.2 | +21% |
| 2021 | $115.2 | $93.3 | -19% |
| 2022 | $93.3 | $101.0 | +8.2% |
| 2023 | $101.0 | $92.9 | -8% |
| 2024 | $92.9 | $128.2 | +38% |
| 2025 | $128.2 | $110.2 | -14% |
| 2026 YTD | $110.2 | $123.7 | +12% |
ADUS has finished lower in three of the last six years. It's up 12% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ADUS on returns for 2026, with the stronger performance.